The influence of concurrent chemoradiotherapy on survival for patients of different ages with stage Ⅳnon-small cell lung cancer——reanalysis of two prospective studies
1 Department of Oncology,Affiliated Hopistal of Guizhou Medical University Teaching and Research Section of Oncology,Guizhou Medical University,Guiyang 550004,China; 2Department of Oncology,Affiliated Hopistal of Guizhou Medical University,Guizhou Cancer Hospital,Guiyang 550004,China; 3Tissue Engineering and Stem Cell Research Center of Guizhou Medical University,Guiyang 550004,China
Abstract：Objective To analyze the survival and toxicity after concurrent chemoradiotherapy in patients of different ages with stage Ⅳ non-small cell lung cancer (NSCLC). Methods Clinical data of 282 NSCLC patients in two prospective studies were retrospectively analyzed,who completed the protocol (at least 2 cycles of chemotherapy and thoracic radiation doses of ≥36 Gy).Among them,44 patients were assigned into in the young group (≤ 45 years old),161 patients in the middle-age group (46-64 years old) and 77 patients in the elderly group (≥ 65 years old).The clinical characteristics of patients among different groups were analyzed by χ2 test. The overall survival (OS) was calculated by Kaplan-Meier method. Stratified analysis was performed by Log-rank test. Multi-factor prognosis analysis was conducted by Cox’s proportional hazards regression model. Results The incidence of NSCLC in the male patients in the elderly group was higher than that in the middle-age and young groups. The 1-,2-,3-and 5-year OS did not significantly differ among different groups (P=0.810).The OS did not significantly differ among patients of the same gender,pathological type,T stage,N stage,metastasis status,same chemotherapy cycle,primary tumor dose and comprehensive treatment and short-term response (all P>0.05).The incidence of adverse events did not considerably differ among different groups. Multivariate analysis demonstrated that age was not an independent factor for survival (P>0.05). Conclusion Patients of different ages with stage Ⅳ NSCLC obtain similar survival benefits and adverse events after concurrent chemoradiotherapy.
Fu Weixu,Ouyang Weiwei,Su Shengfa et al. The influence of concurrent chemoradiotherapy on survival for patients of different ages with stage Ⅳnon-small cell lung cancer——reanalysis of two prospective studies[J]. Chinese Journal of Radiation Oncology, 2019, 28(4): 262-267.
[1] Weir HK,Thun MJ,Hankey BF,et al.Annual report to the nation on the status of cancer.1975-2000,featuring the use of surveillance data for cancer prevention and control[J].J Natl Cancer Inst,2003,95(17):1276-1299.DOI:10.1093/jnci/djg040. [2] Santos FN,Cruz MR,Riera R,et al. Chemotherapy for advanced non-small-cell lung cancer in elderly patients[J].JAMA Oncol,2016,2(12):1645-1646.DOI:10.1001/jamaoncol.2016.2050. [3] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338. [4] Su SF,Li T,Lu B,et al. Three-dimensional radiation therapyto the primary tumor with concurrent chemotherapy in patients with stage Ⅳ non-small cell lung cancer:results of a multicenter phase 2 study from PPRA-RTOG,China[J].Int J Radiat Oncol Biolphys,2015,93(4):769-777.DOI:10.1016/j.ijrobp.2015.08.012. [5] Govindan R,Page N,Morgensztern D,et al. Changing epide-miology of small-cell lung cancer in the United Statesover the last 30 years:analysis of the suveillance epide-miologic,and end results database[J].J Clin Onocol,2006,24(28):4539-4544.DOI:10.1200/JCO.2005.04.4859. [6] Su SF,Hu YX,Ouyang WW,et al. Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage Ⅳ non-small cell lung cancer:results of a prospective single-center study[J]. BMC Cancer,2013,13:474.DOI:10.1186/1471-2407-13-474. [7] 卢冰,苏胜发,何志旭.Ⅳ期NSCLC放疗的回顾与展望[J].中华放射肿瘤学杂志,2018,27(1):29-34.DOI:10.3760/cma.j.issn.1004-4221.2018.01.006. Lu B,Su SF,He ZX.The past,present,and future of radioth-erapy for stage ⅠV non-small cell lung cancer[J].Chin J Radiat Oncolo,2018,27(1):29-34.DOI:10.3760/cma.j.issn.1004-4221.2018.01.006. [8] 龙金华,卢冰,欧阳伟炜,等.Ⅳ期非小细胞肺癌化疗同期胸部三维放疗的前瞻性临床究(三)—不同放疗剂量对生存的影响[J].中华放 射肿瘤学杂志,2012,21(1):23-27.DOI:10.3760/cma.j.issn.1004-4221.2012.01.008. Long JH,Lu B,Ouyang WW,et al. A prospective study on concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage Ⅳ non-small cell lung cancer (3)-The impact of radiation dose to thoracic primary tumor on survival[J].Chin J Radiat Oncolo,2012,21(1):23-27.DOI:10.3760/cma.j.issn.1004-4221.2012.01.008. [9] Kong FM,Wang Wl,Drum G,et al. The effect of thoracic radiation on overall survival and their association with systemic immune therapy in stage Ⅳ NSCLC:Findings from the National Cancer Database[J].J Clin Oncol,2018;36(15S):9103.DOI:10.1200/JCO.2018.36.15_suppl.9103. [10] Iyengar P,Wardak Z,Gerber DE,et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer:a phase 2 randomized clinical trial[J].JAMA Oncol,2017,99(5):e173501.DOI:10.1001/jamaoncol.2017.3501. [11] Gomez DR,Blumenschein GR Jr,Lee JJ,et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy:a multicentre,randomised,controlled,phase 2 study[J].Lancet Oncol,2016,17(12):1672-1682.DOI:10.1016/S1470-2045(16)30532-0. [12] Parikh RB,Cronin AM,Kozono DE,et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer[J].Int J Radiat Oncol,2014,89(4)880-887.DOI:10.1016/j.ijrobp.2014.04.007. [13] Xu Q,Liu H,Xu Y,et al. Local ablative therapy improves survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs[J].Int J Radiat Oncol Biol Phys,2018,102(3S):S90.DOI:10.1016/j.ijrobp.2018.06.241. [14] Su SF,Hu YX,Ouyang WW,et al. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage Ⅳ non-small cell lung cancer?:secondary analysis of two prospective studies[J].BMC Cancer,2016,16(1):908.DOI:10.1186/s12885-016-2952-3. [15] 苏胜发,卢冰,胡银祥,等.NSCLC单器官转移化疗同期原发及转移灶放疗的临床察[J].中华肿瘤防治杂志,2013,20(14):1102-1105. Su SF,Lu B,Hu YX,et al. Survival in patients with non-small cell lung cancer and single organ metastasis treated with thoracic concurrent chemoradiotherapy and metastatic lesions radiotherapy[J].Chin J Cancer Prevent Treat,2013,20(14):1102-1105. [16] 王刚,卢冰,苏胜发,等.Ⅳ期非小细胞肺癌化疗同期胸部三维放疗的前瞻性临床究(二)—不同器官转移状态对生存的影响[J].中华放射肿瘤学杂志,2011;20(6):473-477.DOI:10.3760/cma.j.issn.1004-4221.2011.06.007. Wang G,Lu B,Su SF,et al. A prospective study on concurrent chemotherapy and thoracic three-dimensional radiotherapy for stage Ⅳ non-small cell lung cancer (2) — The impact of different metastasis organs on survival[J].2011,20(6):473-477.DOI:10.3760/cma.j.issn.1004-4221.2011.06.007. [17] Bryant AS,Cerfolio RJ.Differences in outcomes between younger and older patients with non-small cell lung cancer[J].Ann Thorac Surg,2008,85(5):1735-1739.DOI:10.1016/j.athoracsur.2008.01.031. [18] Skarin AT,Herbst RS,Leong TL,et al. Lung cancer in pati-ents under age 40[J].Lung Cancer,2001,14(5):325-340. [19] Subramanian J,Morgensztern D,Goodgame B,et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young:a surveillance,epidemiology,and end results (SEER) analysis[J].J Thorac Oncol,2010,5(1):23-28.DOI:10.1097/JTO.0b013e3181c41e8 d. [20] 张侠,王衍富.老年肺癌的临床现状及流行病学研究[J].中国全科医学,2008,11(7):610-612.DOI:10.3969/j.issn.1007-9572.2008.07.028. Zhang X,Wang YF.Clinical and Epidemic Characteristics of lung cancer in elderly patients[J].Chin Gen Pract,2008,11(7):610-612.DOI:10.3969/j.issn.1007-9572.2008.07.028. [21] Zhang X,Wu L,Xu Y,et al. Trends in the incidence rate of lung cancer by histological type and gender in Sichuan,China,1995-2015:A single-center retrospective study[J].Thorac Cancer,2018.May;9(5):532-541.DOI:10.1111/1759-7714.12601. [22] Alam N,Shepherd FA,Winton T,et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of national cancer institute of Canada and intergroup trial JBR.10 and a review of the literature[J].Lung Cancer,2005,47(3):385-394.DOI:10.1016/i.lungcan.2004.08.016. [23] Gao Y,Gao F,Ma JL,et al. Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients[J].Patient Prefer Adher,2015,9:1189-1194.DOI:10.2147/PPA.S87069. [24] 张波,卢冰,苏胜发,等.老年Ⅳ期非小细胞肺癌三维放疗重要性研究[J].中华放射肿瘤学杂志,2012,21(6):504-507.DOI:10.3760/cma.j.issn.1004-4221.2012.06.006. Zhang B,Lu B,Su SF,et al. The study on importance of three-dimensional radiotherapy for elderly patients with stage Ⅳ non small cell lung cancer[J].2012,21(6):504-507.DOI:10.3760/cma.j.issn.1004-4221.2012.06.006. [25] Kale MS,Mhango G,Gomez JE,et al. Treatment toxicity in elderly patients with advanced non-small cell lung cancer[J].Am J Clin Oncol,2017,40(5):470-476.DOI:10.1097/COC.0000000000000188. [26] Rocha-Lima CM,Herndon JE 2nd,Kosty M,et al. Therapy choices among older patients with lung carcinoma:an evaluation of two trials of the cancer and leukemia group B[J].Cancer,2002,94(1):181-187.DOI:10.1002/cncr.10174. [27] Semrau S,Zettl H,Hildebrandt G,et al. Older patients with inoperable non-small cell lung cancer:long-term survival after concurrent chemoradiotherapy[J].Strahlenther Onkol,2014,190(12):1125-1132.DOI:10.1007/s00066-014-0710-5. [28] Coate LE,Massey C,Hope A,et al. Treatment of the elderly when cure is the goal:the influence of age on treatment selection and efficacy for stage Ⅲ non-small cell lung cancer[J].J Thor Oncol,2011,6(3):537-544.DOI:10.1097/JTO.0b013e31820b8b9b.
2019, Vol. 28 
